Document is current
Any future updates will be listed below
-
Authors
Swift, Michelle L. https://orcid.org/0000-0003-3645-1308
Zhou, Rui https://orcid.org/0000-0002-4491-4811
Syed, Aleem https://orcid.org/0000-0001-7942-3900
Moreau, Lisa A.
Tomasik, Bartłomiej
Tainer, John A.
Konstantinopoulos, Panagiotis A. https://orcid.org/0000-0002-1032-1479
D’Andrea, Alan D. https://orcid.org/0000-0001-6168-6294
He, Yizhou Joseph https://orcid.org/0000-0002-1396-7275
Chowdhury, Dipanjan https://orcid.org/0000-0001-5645-3752
- License Information
-
More Information
Article History
Received: 31 January 2023
Accepted: 21 July 2023
First Online: 11 September 2023
Competing interests
: A.D.D. reports consulting for AstraZeneca, Bayer AG, Blacksmith/Lightstone Ventures, Bristol Myers Squibb, Cyteir Therapeutics, EMD Serono, Impact Therapeutics, PrimeFour Therapeutics, Pfizer, Tango Therapeutics and Zentalis Pharmaceuticals/Zeno Management; is an Advisory Board member for Cyteir and Impact Therapeutics; a stockholder in Cedilla Therapeutics, Cyteir, Impact Therapeutics and PrimeFour Therapeutics, and reports receiving commercial research grants from Bristol Myers Squibb, EMD Serono, Moderna and Tango Therapeutics. The remaining authors declare no competing interests.
